The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Open accessAbstract
BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“At a median follow-up of 11.2 months, PFS was longer in the talazoparib arm (8.6 versus 5.6 months, HR 0.54; 95% CI 0.41-0.71, P < 0.0001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 895
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519
Flagged first, then by citations
Research works printed but not linked: 1
- Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.
Cited by
Sorted by citations
Items 501–600 of 1,000
Khaddour, K., Maahs, L., Rodriguez, A. M. A., Maamar, Y., Samaan, S., & Ansstas, G. (2021) · Cancers · doi:10.3390/cancers13225847 · Cited by 33
Thill, M., Jackisch, C., Janni, W., Müller, V., Albert, U., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Diel, I., et al. (2019) · Breast Care · doi:10.1159/000500999 · Cited by 32
Mehlich, D., & Marusiak, A. A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215775 · Cited by 34
Bagegni, N. A., Davis, A. A., Clifton, K., & Ademuyiwa, F. O. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s293597 · Cited by 32
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
Sorrentino, C., & Carlo, E. D. (2023) · Cancers · doi:10.3390/cancers15112885 · Cited by 32
Incorvaia, L., Perez, A., Marchetti, C., Brando, C., Gristina, V., Cancelliere, D., Pivetti, A., Contino, S., Giovanni, E. D., Barraco, N., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102650 · Cited by 34
Wang, L., Mi, D., Hu, J., Liu, W., Zhang, Y., Wang, C., Chen, Y., & Chen, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216049 · Cited by 30
Gennari, A., Brain, E. G. C., Censi, A. D., Nanni, O., Wuerstlein, R., Frassoldati, A., Cortés, J., Rossi, V., Palleschi, M., Alberini, J. L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.007 · Cited by 30
Kristeleit, R. S., Leary, A. F., Oaknin, A., Redondo, A., George, A. J., Chui, S., Seiller, A., Liste-Hermoso, M., Willis, J., Shemesh, C. S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02776-7 · Cited by 32
Therapeutic advances and application of PARP inhibitors in breast cancer
Zhou, T., & Zhang, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102410 · Cited by 36
Zhu, H., Tian, Y., Chen, H., Qian, Y., Li, J., Niu, D., Zhao, W., Wu, Y., Zhang, X., Tang, T., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101287 · Cited by 30
PARPs and PARP inhibitors: molecular mechanisms and clinical applications
Wang, F., Zhuyi, G. U. O., Carr, M. J., & Shi, W. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00385-1 · Cited by 34
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
Przybyciński, J., Nalewajska, M., Marchelek‐Myśliwiec, M., Dziedziejko, V., & Pawlik, A. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1654458 · Cited by 30
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
Mweempwa, A., & Wilson, M. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.50 · Cited by 32
Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalvès, A., Lee, K.-H., Fehrenbacher, L., Mina, L. A., Diab, S., Woodward, N. E., Yerushalmi, R., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz085 · Cited by 30
Self-citationElmeliegy, M. A., Láng, I., Smolyarchuk, Е. А., Chung, C., Plotka, A., Shi, H., & Wang, D. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14178 · Cited by 30
Pal, T., Agnese, D. M., Daly, M. B., Spada, A. R. L., Litton, J. K., Wick, M. J., Klugman, S. D., Esplin, E. D., & Jarvik, G. P. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0712-x · Cited by 30
Self-citationAtezolizumab in the treatment of metastatic triple-negative breast cancer
Pérez-García, J. M., Soberino, J., Racca, F., Gión, M., Stradella, A., & Cortés, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1769063 · Cited by 29
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Min, A., Kim, K., Jeong, K., Choi, S., Kim, S., Suh, K. J., Lee, K.-H., Kim, S., & Im, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-68176-y · Cited by 31
Self-citationXue, L., Chen, F., Yue, F., Camacho, L., Kothapalli, S., Wei, G., Huang, S., Mo, Q., Ma, F., Li, Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05927-5 · Cited by 33
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
Shao, F., Duan, Y., Zhao, Y., Li, Y., Liu, J., Zhang, C., & He, S. (2021) · Aging · doi:10.18632/aging.202724 · Cited by 31
The PARP Way to Epigenetic Changes
Ummarino, S., Hausman, C., & Ruscio, A. D. (2021) · Genes · doi:10.3390/genes12030446 · Cited by 35
Zhao, Q., Ma, P., Fu, P., Wang, J., Wang, K., Chen, L., & Yang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.912256 · Cited by 30
The BRCAness Landscape of Cancer
Guo, M., & Wang, S. M. (2022) · Cells · doi:10.3390/cells11233877 · Cited by 30
Peng, W., Jin, X., Xu, X., Yang, Y., Ma, D., Shao, Z., & Jiang, Y. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2143 · Cited by 31
Militello, A. M., Zielli, T., Boggiani, D., Michiara, M., Naldi, N., Bortesi, B., Zanelli, P., Uliana, V., Giuliotti, S., & Musolino, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00759 · Cited by 30
Morrison, L., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers15153801 · Cited by 29
Ferro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 31
Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer
Rezoug, Z., Totten, S. P., Szlachtycz, D., Atayan, A., Mohler, K., Albert, S., Feng, L., Anglin, B. L., Shen, Z. Z., Jimenez, D., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.31427 · Cited by 32
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sriramulu, S., Thoidingjam, S., Speers, C. W., & Nyati, S. (2024) · Cancers · doi:10.3390/cancers16193250 · Cited by 30
Parp Inhibitors: A Tsunami of Indications in Different Malignancies
Haddad, G., Saadé, M. C., Eid, R., Haddad, F., & Kourié, H. R. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0113 · Cited by 29
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 28
Cortesi, L., Piombino, C., & Toss, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040245 · Cited by 32
Sankaranarayanan, R. A., Peil, J., Vogg, A. T. J., Bolm, C., Terhorst, S., Claßen, A., Bauwens, M., Maurer, J., Mottaghy, F. M., & Morgenroth, A. (2022) · Cancers · doi:10.3390/cancers14010230 · Cited by 29
Advances in cGAS-STING Signaling Pathway and Diseases
Yang, Y., Huang, Y., & Zeng, Z. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.800393 · Cited by 31
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 30
Garufi, G., Carbognin, L., Schettini, F., Seguí, E., Leone, A. D., Franco, A., Paris, I., Scambia, G., Tortora, G., & Fabi, A. (2022) · Cancers · doi:10.3390/cancers14174064 · Cited by 28
He, R., Yuan, X., Chen, Z., & Zheng, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109444 · Cited by 29
Xu, B., Sun, T., Shi, Y., Cui, J., Yin, Y., Ouyang, Q., Liu, Q., Zhang, Q., Chen, Y., Wang, S., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06785-z · Cited by 29
Li, X., Poire, A., Jeong, K. J., Zhang, D., Ozmen, T. Y., Chen, G., Sun, C., & Mills, G. B. (2024) · Nature Communications · doi:10.1038/s41467-024-48637-y · Cited by 31
López‐Cortés, A., Cabrera‐Andrade, A., Echeverría‐Garcés, G., Echeverría-Espinoza, P., Pineda-Albán, M., Elsitdie, N., Bueno‐Miño, J., Segundo, C. M. C., Dorado, J., Pazos, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68565-7 · Cited by 28
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Agelidis, A. M., Ter‐Zakarian, A., & Jaloudi, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516125 · Cited by 38
Kolberg, H., Schneeweiß, A., Fehm, T. N., Wöckel, A., Huober, J., Pontones, C. A., Titzmann, A., Belleville, E., Lux, M. P., Janni, W., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0887-0861 · Cited by 28
Self-citationHe, J., Tsang, J. Y., Xu, X., Li, J., Li, M., Chao, X., Xu, Y., Luo, R., Tse, G. M.-K., & Sun, P. (2020) · BMC Cancer · doi:10.1186/s12885-019-6494-3 · Cited by 28
Patil, A., Narvenker, R., Prabhakar, B. R., & Shende, P. K. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119563 · Cited by 28
Hasson, S. P., Menes, T. S., & Sonnenblick, A. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s233485 · Cited by 28
Heeke, A. L., Xiu, J., Elliott, A., Korn, W. M., Lynce, F. C., Pohlmann, P. R., Isaacs, C. J., Swain, S. M., Vidal, G. A., Schwartzberg, L. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05849-2 · Cited by 28
Ali, R., Alblihy, A., Toss, M. S., Algethami, M., Sunni, R. A., Green, A. R., Rakha, E. A., & Madhusudan, S. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920974201 · Cited by 28
Morice, P., Coquan, E., Weiswald, L., Lambert, B., Vaur, D., & Poulain, L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01295-z · Cited by 29
Huang, J., Chen, Z., Ding, C., Lin, S., Wan, D., & Ren, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.711402 · Cited by 28
Lawrence, M. G., Porter, L. H., Choo, N., Pook, D. W., Grummet, J., Pezaro, C. J., Sandhu, S. K., Ramm, S., Luu, J., Bakshi, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0932 · Cited by 31
Roles of Protein Disulfide Isomerase in Breast Cancer
Yang, S., Jackson, C., Karapetyan, E., Dutta, P., Kermah, D., Wu, Y., Wu, Y., Schloss, J. V., & Vadgama, J. V. (2022) · Cancers · doi:10.3390/cancers14030745 · Cited by 31
Bonadio, R. C., Tarantino, P., Testa, L., Punie, K., Pernas, S., Barrios, C. H., Curigliano, G., Tolaney, S. M., & Barroso‐Sousa, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102459 · Cited by 28
Bobrie, A., Massol, O., Ramos, J., Mollévi, C., Lopez‐Crapez, E., Bonnefoy, N., Boissière‐Michot, F., & Jacot, W. (2022) · Cancers · doi:10.3390/cancers14194829 · Cited by 28
Zheng, J., Li, Z., & Min, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979873 · Cited by 28
Willing, E., Vollbrecht, C., Vössing, C., Weist, P., Schallenberg, S., Herbst, J., Schatz, S., Jóri, B., Bataillon, G., Harter, P., et al. (2023) · Cancers · doi:10.3390/cancers15133445 · Cited by 29
Sammons, S. L., Shastry, M., Dent, S. F., Anders, C. K., & Hamilton, E. P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.017 · Cited by 28
Li, S., Hao, L., Li, N., Hu, X., Yan, H., Dai, E., & Shi, X. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5676 · Cited by 36
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 28
Korean Hereditary Breast Cancer Study Group, Ryu, J. M., Choi, H. J., Kim, I., Nam, S. J., Kim, S. W., Yu, J., Lee, S. K., Choi, D. H., Park, Y. H., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5015-4 · Cited by 27
Baldwin, P., Öhman, A., Medina, J. E., McCarthy, E. T., Dinulescu, D. M., & Sridhar, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00353 · Cited by 27
Vidula, N., Dubash, T. D., Lawrence, M. S., Simoneau, A., Niemierko, A., Blouch, E. L., Nagy, B., Roh, W., Chirn, B., Reeves, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0638 · Cited by 27
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures
Bodily, W. R., Shirts, B. H., Walsh, T., Gülsüner, S., King, M., Parker, A., Roosan, M. R., & Piccolo, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239197 · Cited by 27
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey, N., Aske, J. C., & Pradip, D. (2021) · Pharmaceuticals · doi:10.3390/ph14050455 · Cited by 26
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
Имянитов, Е. Н., & Соколенко, А. П. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i7.544 · Cited by 27
Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?
Gupta, R. K., Roy, A. M., Gupta, A. K., Takabe, K., Dhakal, A., Opyrchal, M., Kaliński, P., & Gandhi, S. (2022) · Cancers · doi:10.3390/cancers14081856 · Cited by 28
Addressing the routine failure to clinically identify monogenic cases of common disease
Murray, M. F., Khoury, M. J., & Abul‐Husn, N. S. (2022) · Genome Medicine · doi:10.1186/s13073-022-01062-6 · Cited by 28
Caramelo, O. L., Silva, C., Caramelo, F. J., Frutuoso, C., Pinto, L., & Almeida‐Santos, T. (2022) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-022-00242-0 · Cited by 27
Development of a novel BRCAness score that predicts response to PARP inhibitors
Oshi, M., Gandhi, S., Wu, R., Asaoka, M., Yan, L., Yamada, A., Yamamoto, S., Narui, K., Chishima, T., Ishikawa, T., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00427-8 · Cited by 25
Small molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 27
Gabbasov, R. T., Benrubi, I. D., O’Brien, S. W., Krais, J. J., Johnson, N., Litwin, S., & Connolly, D. C. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595279 · Cited by 27
Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation
Rattanaburee, T., Tipmanee, V., Tedasen, A., Thongpanchang, T., & Graidist, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110361 · Cited by 28
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy
Subhan, M. A., & Torchilin, V. P. (2024) · Bioengineering · doi:10.3390/bioengineering11080830 · Cited by 26
Signaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 31
Genomic Alteration in Metastatic Breast Cancer and Its Treatment
Li, A., Schleicher, S. M., André, F., & Mitri, Z. I. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280463 · Cited by 26
Caracciolo, D., Riillo, C., Arbitrio, M., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33038 · Cited by 29
Update on multi‐gene panel testing and communication of genetic test results
Reid, S., & Pal, T. (2020) · The Breast Journal · doi:10.1111/tbj.13971 · Cited by 26
Shi, J., Liu, F., & Song, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s272685 · Cited by 26
Liu, X., Wu, K., Zheng, D., Luo, C., Fan, Y., Zhong, X., & Zheng, H. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742139 · Cited by 26
Garcia, E. P., de Luna, I. F., Persad, K. L., Agopsowicz, K. C., Jay, D., West, F. G., Hitt, M., & Persad, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-91344-7 · Cited by 26
Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors
Chi, Z., Bai, Y., Li, J., Wang, K., Xu, Y., & Luan, Y. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128821 · Cited by 26
Dixon-Douglas, J. R., Loibl, S., Denkert, C., Telli, M. L., & Loi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351186 · Cited by 27
Li, S., Bao, C., Huang, L., & Wei, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206021 · Cited by 28
Palazzo, A., Ciccarese, C., Iacovelli, R., Cannizzaro, M. C., Stefani, A., Salvatore, L., Bria, E., & Tortora, G. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101154 · Cited by 32
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
Agnello, L., d’Argenio, A., Nilo, R., Fedele, M., Camorani, S., & Cerchia, L. (2023) · Cancers · doi:10.3390/cancers15072010 · Cited by 25
Nicolussi, A., Belardinilli, F., Mahdavian, Y., Colicchia, V., D'inzeo, S., Petroni, M., Zani, M., Ferraro, S., Valentini, V., Ottini, L., et al. (2019) · PeerJ · doi:10.7717/peerj.6661 · Cited by 26
Kagihara, J. A., Andress, M., & Diamond, J. R. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1730694 · Cited by 25
Pellegrino, B., Cavanna, L., Boggiani, D., Zamagni, C., Frassoldati, A., Schirone, A., Caldara, A., Rocca, A., Gori, S., Piacentini, F., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100019 · Cited by 25
Kalra, M., Tong, Y., Jones, D. R., Walsh, T., Danso, M. A., Ma, C. X., Silverman, P., King, M., Badve, S., Perkins, S. M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00240-w · Cited by 26
Paluch–Shimon, S., & Cardoso, F. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00452-2 · Cited by 26
Pop, L. G., Suciu, I. D., Ionescu, O., Bacalbașa, N., & Ionescu, P. (2021) · Journal of Medicine and Life · doi:10.25122/jml-2020-0132 · Cited by 25
The biology and treatment of leiomyosarcomas
Kerrison, W. G. J., Thway, K., Jones, R. L., & Huang, P. H. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103955 · Cited by 32
Myers, S. H., Poppi, L., Rinaldi, F., Veronesi, M., Ciamarone, A., Previtali, V., Bagnolini, G., Schipani, F., Martínez, J. A. O., Girotto, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116114 · Cited by 27
Aljuhani, A., Nafie, M. S., Albujuq, N. R., Alsehli, M., Bardaweel, S. K., Darwish, K. M., Al‐Raqa, S. Y., Aouad, M. R., & Rezki, N. (2025) · RSC Advances · doi:10.1039/d4ra07540d · Cited by 25
Bonnefoi, H. R., Lerebours, F., Pulido, M., Arnedos, M., Trédan, O., Dalenc, F., Guiu, S., Teixeira, L., Mollon, D., Levy, C., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00737-x · Cited by 27
Emerging Novel Therapeutics in Triple-Negative Breast Cancer
Lyons, T. G., & Traina, T. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_20 · Cited by 25
Mapping genetic interactions in cancer: a road to rational combination therapies
Tutuncuoglu, B., & Krogan, N. J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0680-4 · Cited by 25
Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients
Kim, E., Park, S. Y., & Kim, S. (2020) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2020.04.07 · Cited by 25
Freitag, C. E., Mei, P., Wei, L., Parwani, A. V., & Li, Z. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.05.005 · Cited by 25
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Cipriano, É., & Mesquita, A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211002491 · Cited by 26
Metadata
- Authors
- Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y.-H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L.
- Affiliations
- Kaiser Permanente (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-23
- Volume
- 379
- Issue
- 8
- Pages
- 753-763
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10600918
- OpenAlex
- W2886477543
- Cited by
- 2,175
- References
- 14
- Citations by year
- 2026: 195 · 2025: 241 · 2024: 254 · 2023: 312 · 2022: 356 · 2021: 319 · 2020: 280 · 2019: 195 · 2018: 20
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- PARP inhibitors, advanced breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, progression-free survival, objective response rate, hematologic adverse events, anemia, patient-reported outcomes, quality of life, single-agent chemotherapy, capecitabine, eribulin, gemcitabine, vinorelbine, PARP inhibitor resistance, PARP inhibitor combination therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Patient Reported Outcome Measures, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Phthalazines, Quality of Life, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
